Concurrent chemoradiotherapy of capecitabine with or without oxaliplatin versus cisplatin with fluorouracil for treatment of squamous oesophageal cancer in Chinese patients (CRTCOESC): an interim report of a randomised, open-label, multicentre trial

卡培他滨 医学 奥沙利铂 中期分析 内科学 临床终点 放化疗 不利影响 肿瘤科 临床试验 癌症 结直肠癌
作者
Ruinuo Jia,Tanyou Shan,Fuyou Zhou,Anping Zheng,Lixin Wan,Zhiqiao Xu,Guobao Zheng,Xiaoyong Luo,Yingjuan Zheng,Yanhui Cui,Guifang Zhang,Dan Zhou,Jiachun Sun,Guoqiang Kong,Xiaozhi Yuan,Yang Ruina,Jing Ren,Wei Wang,Xinshuai Wang,Shegan Gao
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:18: S4-S4 被引量:3
标识
DOI:10.1016/s1470-2045(17)30760-x
摘要

Abstract Background Chemoradiotherapy with fluorouracil and cisplatin (PF) has shown greater clinical efficacy for local advanced oesophageal cancer but with high rate of acute toxicities. We designed the CRTCOESC study to evaluate the effect and safety of capecitabine with or without oxaliplatin versus PF with chemoradiotherapy in Chinese patients with oesophageal cancer. Methods We this randomised, open-label, multicentre trial in nine cancer centres in Henan province, China, in Chinese patients with biopsy-proven squamous oesophageal cancer (T2-4N0-2M0). We randomly assigned patients (1:1:1) to receive single capecitabine, capecitabine plus oxaliplatin, or PF, and every patient received daily radiation of 50 Gy in 2 Gy dose per fraction. Patients were stratified by different regimens cycles. Both grade 3–5 acute toxicities and 2-year overall survival were the primary endpoint, with a planned accrual of 249 patients to detect a decrease in grade 3–5 acute toxicities from 40% to 20%. Interim analysis of acute toxicities and overall response was planned for the first 120 patients. This study is registered with ClinicalTrials, number NCT02025036. Findings Between October, 2014, and December, 2016, we accrued 128 patients, of whom 118 were eligible. 86 patients finished at least 16 weeks' follow-up and were included in the interim report (n=24 capecitabine group, n=37 capecitabine plus oxaliplatin group, and n=25 PF group). Pretreatment characters (age, gender, weight, performance status, clinical stage, lymphonodus status, and pathology grade) did not differ between the groups. Incidence of grade 3–5 acute toxicities was 25% in the capecitabine group, 32% in the capecitabine plus oxaliplatin group, and 64% in the PF group (p=0·03); the incidence was significantly lower in the capectitabine groups than the PF group (capectitabine vs PF p=0·041; capecitabine plus oxaliplatin vs PF p=0·022) and did not differ between capectitabine and capecitabine plus oxaliplatin (p=0·738). 56 patients had finished 1-year follow-up (n=12 capecitabine group, n=26 capecitabine plus oxaliplatin group, and n=18 PF group). The 1-year overall survival was 75% in the capecitabine group, 92% in the capecitabine plus oxaliplatin group, and 76% in the PF group (p=0·166). Nine patients died in total: three patients in the capecitabine group, two patients in the capecitabine plus oxaliplatin group, and four patients in the PF group. Interpretation Compared with PF, chemoradiotherapy with single capecitabine with or without oxaliplatin showed lower incidence of acute toxicities and similar 1-year overall survival. Funding National Natural Science Foundation of China.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
黄加豪发布了新的文献求助30
刚刚
刚刚
南枝叙发布了新的文献求助10
刚刚
1秒前
没窗没门完成签到,获得积分10
1秒前
SciGPT的应助被皮蛋s周采纳,获得10
1秒前
1秒前
踏实的含芙完成签到,获得积分20
2秒前
在水一方的应助被MrLiu采纳,获得10
2秒前
卑微小李完成签到,获得积分10
3秒前
顾矜的应助被xushanqi采纳,获得10
3秒前
yuzhuoWng发布了新的文献求助10
3秒前
852的应助被chnningji采纳,获得10
4秒前
呜呜呜发布了新的文献求助10
4秒前
4秒前
我爱吃糯米团子完成签到,获得积分10
5秒前
xyq030323发布了新的文献求助10
5秒前
赵一娟发布了新的文献求助10
5秒前
丘比特的应助被111采纳,获得10
5秒前
fanfan发布了新的文献求助10
5秒前
风趣紫发布了新的文献求助10
5秒前
5秒前
6秒前
煜琪完成签到 ,获得积分10
6秒前
FashionBoy的应助被夭夭采纳,获得10
6秒前
Haosen完成签到,获得积分10
7秒前
yu完成签到,获得积分10
7秒前
7秒前
无情的聪健的应助被wy采纳,获得20
7秒前
7秒前
7秒前
孙佳烨发布了新的文献求助10
8秒前
科研小白完成签到,获得积分10
8秒前
Hazzz完成签到,获得积分10
8秒前
8秒前
bkagyin的应助被小雷神采纳,获得10
8秒前
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8154571
求助须知:如何正确求助?哪些是违规求助? 9551133
关于积分的说明 21702959
捐赠科研通 7743886
什么是DOI,文献DOI怎么找? 3425867
关于科研通互助平台的介绍 2551036
邀请新用户注册赠送积分活动 2469522